Detalhe da pesquisa
1.
Clinical characteristics and management of orbital apex syndrome: a 10-year multicentre experience.
Rhinology
; 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38752541
2.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Ann Oncol
; 33(6): 616-627, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337972
3.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Ann Oncol
; 32(2): 197-207, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186740
4.
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Ann Oncol
; 31(11): 1526-1535, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32828825
5.
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ann Oncol
; 29(9): 1939-1947, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30124753
6.
Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial.
Ann Oncol
; 28(11): 2761-2767, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29112701
7.
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Support Care Cancer
; 25(2): 505-511, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27709313
8.
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Ann Oncol
; 26(12): 2429-36, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26387142
9.
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.
Br J Cancer
; 110(2): 384-91, 2014 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24346286
10.
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Ann Oncol
; 25(6): 1116-21, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685829
11.
Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients.
Ann Oncol
; 25(2): 346-51, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24379161
12.
Clinical relevance of TNM staging system according to breast cancer subtypes.
Ann Oncol
; 30(12): 2011, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31408085
13.
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.
Ann Oncol
; 24(10): 2630-2635, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23868905
14.
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
Ann Oncol
; 24(6): 1485-90, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23380385
15.
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
Invest New Drugs
; 31(5): 1300-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23677653
16.
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Nat Genet
; 23(2): 222-7, 1999 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-10508522
17.
Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.
Br J Cancer
; 106(5): 923-30, 2012 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22294188
18.
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.
Br J Cancer
; 104(4): 559-63, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21285992
19.
Clinical relevance of TNM staging system according to breast cancer subtypes.
Ann Oncol
; 22(7): 1554-1560, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21242587
20.
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Br J Cancer
; 103(6): 845-51, 2010 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20700125